Table 3:
Comparison of the frequency of DRMs between 1st and 2nd line recipients
| Mutations | Total n (%) |
1st line 112(70%) |
2nd line 48(30%) |
P value |
|---|---|---|---|---|
| Total DRMs | 137(86) | 105(94) | 32(67) | P<0.001* |
| NRTIs | 96(60) | 80(71) | 16(33) | P<0.001* |
| M184V | 85(53) | 73(65) | 12(25) | P<0.001* |
| K65R | 41(25) | 38(34) | 3(6) | P<0.001* |
| K70R | 9(6) | 6(5) | 3(6) | P=0.812 |
| TAMs | 38(24) | 29(26) | 9(19) | P=0.345 |
| NNRTIs | 137(85) | 105(93) | 32(67) | P<0.001* |
| K103N | 58(36) | 51(45) | 7(15) | P<0.001* |
| Y181C | 45(28) | 31(27) | 14(29) | P=0.82 |
| G190A | 57(35) | 44(39) | 13(27) | P=0.150 |
| V106AM | 45(28) | 41(36) | 4(8) | P<0.001* |
| Mutations to NRTIs+NNRTIs | 96(60) | 80(71) | 16(33) | P<0.001* |
| PI mutations | 5(3) | 0 | 5(10) | # |
| M46I | 4(3) | 0 | 4(8) | # |
| N88S | 2(1) | 0 | 2(4) | # |
| I84IV | 1(1) | 0 | 1(2) | # |
DRMs drug resistance mutations; NRTIs nucleoside/nucleotide reverse transcriptase inhibitors; TAMs thymidine analogue mutations; NNRTIs non-NRTIs, PI protease inhibitor; 1st line regimen was comprised of 2NRTIs+ NNRTI; 2nd line regimen was comprised of 2NRTIs + PI; # not computed.